Turning Point Brands (TPB) saw its stock skyrocket 14.08% in intraday trading on Wednesday, following the release of its impressive first-quarter 2025 financial results and heightened demand for its smokeless tobacco products. The company, known for its tobacco and alternative products, significantly outperformed market expectations, driving investor enthusiasm.

The quarterly report revealed that Turning Point's sales reached $106.44 million, handily beating the analyst consensus estimate of $95.75 million by 11.16%. This represents a robust 9.66% increase compared to the same period last year. The company's adjusted earnings per share (EPS) came in at $0.91, surpassing the expected $0.78 by 16.67% and showing a 13.75% year-over-year growth.

A key driver of Turning Point's success was the surging demand for its Modern Oral smokeless tobacco products. Sales of the Modern Oral brand rose almost tenfold to $22.3 million, contributing significantly to the 63% increase in Stoker's smokeless tobacco sales. In response to this strong performance, Turning Point boosted its projection for 2025 Modern Oral sales to a range between $80 million and $95 million, up from its prior forecast of $60 million to $80 million. This optimistic outlook, combined with the company's reaffirmed 2025 Adjusted EBITDA guidance of $108.0 - $113.0 million, has fueled investor confidence and contributed to the stock's dramatic rise.